Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04381832 · ClinicalTrials.gov registry record · Phase 1
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 173
- Enrollment target
NCT04381832 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 173 participants.
The verdict
NCT04381832, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 173 participants
- Enrollment target
Study Summary
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Interventions
- DRUG Docetaxel
- DRUG Zimberelimab
- DRUG Quemliclustat
- DRUG Enzalutamide
- DRUG Etrumadenant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2020-07-07 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04381832
The ClinicalTrials.gov registry entry for NCT04381832 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT04381832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04381832 about?
NCT04381832 is a clinical study titled "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer". This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
What is the current status of trial NCT04381832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 173 participants. The study started on 2020-07-07. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04381832?
The interventions under investigation include: Docetaxel (DRUG), Zimberelimab (DRUG), Quemliclustat (DRUG), Enzalutamide (DRUG), Etrumadenant (DRUG).
Who is sponsoring clinical trial NCT04381832?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.